Nav: Home > Coffee News >

Caffeine reduces the risk of Alzheimer's disease

Published: 2025-12-07 Author: World Gafei

Last Updated: 2025/12/07, Research by Dr. David Bluem of the French Institute of Health and Medicine and Lille laboratory staff has shown that caffeine has a good effect on some brain diseases, especially Alzheimer's disease (commonly known as "Alzheimer's disease").

Research by Dr. David Bluem of the French Institute of Health and Medicine and Lille laboratory staff has shown that caffeine has a good effect on some brain diseases, especially Alzheimer's disease (commonly known as "Alzheimer's disease"). Although the findings, published in the American Journal of Geriatric Neurobiology, have only been confirmed in mice, long-term coffee drinkers can still offer comfort.

It is reported that cognitive changes in Alzheimer's disease are the result of two diseases, and it is well known that regular caffeine intake can effectively inhibit cognitive decline during aging and reduce the risk of further development of dementia. However, the pathological effect of caffeine remains to be further explained.

The researchers conducted experiments on transgenic mice, which gradually developed neurodegenerative symptoms associated with related proteins as they grew older. The researchers fed caffeine orally to mice over a period of 10 months. Bluem said in a bulletin of the French Institute of Health and Medicine that the results showed that caffeine-fed mice had mild pathological changes in memory, related protein lesions and neuroinflammation. The mice were given a moderate dose of caffeine, equivalent to two cups of coffee a day for the average person, the report said.

The study of caffeine has successfully provided experimental evidence of a link between caffeine intake and the pathology associated with related proteins. The study also shows that caffeine has a good effect on other brain disorders in addition to Alzheimer's disease. Dr Miller, who co-led the study, developed a molecule with a similar effect to caffeine. The molecule is even better than caffeine in mice with dementia, Agence France-Presse reported.

Bluem said the experiment made a significant contribution to the influencing factors of Alzheimer's disease. He pointed out that based on the findings, on the one hand, people hope to identify the molecules that make caffeine have this effect, and on the other hand, they hope to conduct clinical trials on the efficacy of caffeine in patients with Alzheimer's disease.